MT-2111 marketing authorisation application for relapsed or refractory DLBCL
A specific drug theme involving the filing of a marketing authorisation application for MT-2111 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.